Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Odefsey

- PMLiVE

Russian HIV vaccine heading for phase II trials

But trials could be affected by lack of funding

Gilead Sciences

Gilead gets US approval for Sovaldi follow-up Harvoni

Company claims it could cure 90 percent of patients within eight weeks

- PMLiVE

EMA draws fire on new clinical reports policy

Has recently come under pressure from transparency groups

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

Gilead will file safer HIV combination before year-end

New version of Stribild is less likely to cause side effects

EU flag

EC slammed for pharma oversight changes

Organisations criticise decision to transfer responsibility for pharma policy from health to industrial department

European Commissioner for health and food safety elected

Vytenis Andriukaitis will take on the role from October

- PMLiVE

H4B’s charity team launches Catalyst4Change

The comms agency aims to 'help smaller charities be heard'

- PMLiVE

BMS can ride on Sovaldi’s success as Daklinza cleared in EU

Hepatitis C drug approved in combination with Gilead’s huge-selling treatment

- PMLiVE

ViiV bags US approval for HIV blockbuster-in-waiting

Drug combines antiretrovirals with Tivicay

- PMLiVE

NICE backs Gilead’s Sovaldi in hepatitis C

But health watchdog denies earlier use of Janssen’s Zytiga

- PMLiVE

Roche’s Avastin gets new EU nod in ovarian cancer

Wins new approval for hard-to-treat platinum-resistant recurrent form of disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links